Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters








Year range
1.
Journal of Central South University(Medical Sciences) ; (12): 1457-1463, 2020.
Article in English | WPRIM | ID: wpr-880607

ABSTRACT

Antipsychotic medication is the primary treatment for schizophrenia, which is effective on ameliorating positive symptoms and can reduce the risk of recurrence, but it has limited efficacy for negative symptoms and cognitive dysfunction. The negative symptoms and cognitive dysfunction seriously affects the life quality and social function for the patients with schizophrenia. Currently, there is plenty evidence that antipsychotic drugs combined with adjuvant therapy drugs can effectively improve the negative symptoms and cognitive dysfunction. These drugs include anti-oxidants, nicotinic acetylcholine receptors and neuro-inflammatory drugs (anti-inflammatory drugs, minocycline), which show potential clinical effects.


Subject(s)
Humans , Anti-Inflammatory Agents/therapeutic use , Antipsychotic Agents/therapeutic use , Cognitive Dysfunction/etiology , Minocycline/therapeutic use , Schizophrenia/drug therapy
2.
Journal of Central South University(Medical Sciences) ; (12): 701-705, 2019.
Article in Chinese | WPRIM | ID: wpr-813247

ABSTRACT

The negative symptoms and cognitive symptoms of schizophrenia patients are still clinical problems to be solved. Schizophrenia patients are abnormal in oxidative stress, immune regulation, and anti-histone deacetylase (HDAC), while sulforaphane plays a role in anti-oxidative stress, anti-inflammation, and anti-HDAC. Therefore, the sulforaphane could improve the negative symptoms and cognitive deficits of schizophrenia.


Subject(s)
Humans , Cognition , Isothiocyanates , Therapeutic Uses , Schizophrenia , Drug Therapy
SELECTION OF CITATIONS
SEARCH DETAIL